A carregar...
Novel ovarian cancer maintenance therapy targeted at mortalin and mutant p53
Current ovarian cancer maintenance therapy is limited by toxicity and no proven impact on overall survival. To study a maintenance strategy targeted at missense mutant p53, we hypothesized that the release of mutant p53 from mortalin inhibition by the SHetA2 drug combined with reactivation of mutant...
Na minha lista:
| Publicado no: | Int J Cancer |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7297651/ https://ncbi.nlm.nih.gov/pubmed/31845320 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ijc.32830 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|